Anatomical and Biological Considerations to Determine Resectability in Pancreatic Cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a dismal 5-year survival rate of 12%.
• Late diagnosis and early systemic spread contribute to poor patient outcomes.
• Despite aggressive surgical interventions, approximately 40% of patients experience early disease recurrence.

Purpose of the Study:

• To review current literature on defining anatomical and biological resectability in pancreatic cancer.
• To explore integrating biological criteria into staging systems to improve surgical decision-making.
• To identify patients most likely to benefit from aggressive surgical resection.

Main Methods:

• Literature review of anatomical and biological factors influencing pancreatic cancer resectability.
• Analysis of current anatomical staging systems for pancreatic cancer.
• Discussion of the impact of systemic disease burden on surgical outcomes.

Main Results:

• Anatomical staging systems alone do not account for systemic disease burden.
• Patients with anatomically resectable disease but undetected systemic disease may not benefit from resection.
• Integrating biological criteria could help select patients for complex resections who are likely to benefit.

Conclusions:

• Current anatomical staging for pancreatic cancer may lead to futile resections.
• Incorporating biological assessment alongside anatomical staging is crucial for optimizing treatment strategies.
• A combined approach can help avoid unnecessary morbidity and improve survival for select pancreatic cancer patients.